Sanofi India Limited has informed the Exchange regarding outcome of the Board Meeting of the Company held on Wednesday, 14th May 2025
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's Board approved its Q1 2025 unaudited financial results on May 14, 2025. Net sales grew 4% year-on-year on a comparable basis (continuing business), driven by the steady ramp-up of its diabetes drug Soliqua®. Revenue from operations rose to ₹5,359 million from ₹5,108 million in Q1 2024. Operating profit jumped 27% to ₹1,653 million (vs ₹1,312 million), helped by lower total expenses of ₹3,739 million (down from ₹3,831 million). Profit from continuing operations surged to ₹1,195 million from ₹720 million, translating to EPS of ₹51.89 (vs ₹31.26). Note: Q1 2024 figures were impacted by an exceptional personnel separation cost of ₹267 million, and the Consumer Healthcare business has been classified as discontinued operations following its June 2024 demerger.
Positive quarter for shareholders — strong double-digit growth in operating profit and EPS signals improving cost efficiency and pricing power in the core pharma business. The optics are partly aided by a low base (exceptional cost in Q1 2024) and the demerger of Consumer Healthcare, so underlying momentum should be assessed on the continuing-business basis.